Research
Energy balance
Clinical trials of tirzepatide have demonstrated cardiovascular safety in high-risk patients.
Tirzepatide may be considered safe for use in patients at high cardiovascular risk.
StrongSupportsmedium confidence
To date, clinical trials of tirzepatide have fulfilled the requirement by regulatory authorities of demonstrated cardiovascular safety in high-risk patients.
Why this rating
The claim is based on clinical trials, indicating high-quality evidence.
Source
Cardiovascular effects of tirzepatide
Priya Sumithran et al. · Journal of Endocrinology · 2025
DOI 10.1530/joe-24-0259
otherCited 6×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Tirzepatide demonstrates unprecedented efficacy for glycaemic control, reductions in body weight, and improvements in blood pressure and lipid profile compared with placebo and GLP-1 receptor agonists.Strong
- The cardiovascular benefits of dual GLP-1/GIP receptor agonists like tirzepatide remain uncertain.Strong
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →